-
公开(公告)号：US07011846B2
公开(公告)日：2006-03-14
申请号：US10324954
申请日：2002-12-20
IPC分类号： A61K9/48
CPC分类号： A61K9/4866 , A61K47/12 , A61K47/14 , A61K47/34
摘要： A formulation for a stabilized capsule for oral administration of a hydrophobic pharmaceutically active agent; comprising a non-aqueous solubilizer selected from 2-pyrrolidone, N-alkylpyrrolidones and combinations thereof; and a capsule stabilizing agent selected from mono-, di- and triglycerides, mono- and di-fatty esters of polyethylene glycol, fatty acids and combinations thereof wherein capsule integrity is maintained for at least 24 hours is disclosed.
摘要翻译： 用于口服施用疏水性药物活性剂的稳定化胶囊剂的制剂; 包括选自2-吡咯烷酮，N-烷基吡咯烷酮及其组合的非水增溶剂; 以及选自单甘油三酯，甘油二酯和甘油三酯的胶囊稳定剂，聚乙二醇的单脂肪和二脂肪酸酯，脂肪酸及其组合，其中胶囊完整性保持至少24小时。
-
2.发明授权Self-emulsifying formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability and/or reduced food effect 失效非诺贝特和/或非诺贝特衍生物的自乳化制剂具有改善的口服生物利用度和/或降低的食物效应公开(公告)号：US07022337B2
公开(公告)日：2006-04-04
申请号：US10607719
申请日：2003-06-27
IPC分类号： A61K9/48
CPC分类号： A61K9/4866 , A61K9/1075 , A61K9/4858 , A61K31/216 , Y02A50/393
摘要： A fibrate self-emulsifying oral formulation with improved bioavailability when compared to commercially available formulations containing a therapeutically effective dose of fenofibrate, derivative of fenofibrate or mixtures thereof dissolved in a fibrate solubilizer selected from N-alkyl derivative of 2-pyrrolidone, mono- or di- or polyethylene glycol monoethers, C8-12 fatty acid mono- or di-esters of propylene glycol, or combinations thereof, one or more surfactants and optionally one or more stabilizers useful in the treatment of hypercholesterolaemia or hypertriglyceridaemia in mammals in the fed or fasted state.
摘要翻译： 与可商购获得的制剂相比，具有改善的生物利用度的贝特类自乳化口服制剂与含有治疗有效剂量的非诺贝特，非诺贝特衍生物或其混合物的溶解在选自2-吡咯烷酮N-烷基衍生物，单 - 或二 - 或聚乙二醇单醚，C 8-12脂肪酸丙二醇的单酯或二酯或其组合，一种或多种表面活性剂和任选的一种或多种稳定剂，其可用于治疗高胆固醇血症或 哺乳动物在喂食或禁食状态下的高甘油三酯血症。
-
3.发明授权Fluidization of particles for encapsulation in oral dosage pharmaceutical products 失效用于封装口服剂量药物产品的颗粒流化公开(公告)号：US06772801B1
公开(公告)日：2004-08-10
申请号：US10437397
申请日：2003-05-14
IPC分类号： B65B120
CPC分类号： A61K9/5089 , A61J3/074 , B65B1/38
摘要： Encapsulated oral dosage pharmaceutical products are produced utilizing a system including a hopper and a dosator, where the hopper receives particles having irregular geometries and sizes greater than about 100 &mgr;m for delivery to the dosator. A gaseous fluid is directed into the hopper to fluidize particles within the hopper so as to minimize or eliminate the formation of voids within the bed of particles disposed within the hopper. The fluidization of the particles within the hopper maintains a substantially continuous and uniform flow of particles from the hopper to the dosator, which results in the formation of encapsulated products with desirable weights and particle size distributions.
摘要翻译： 使用包括料斗和剂量器的系统生产包封的口服剂量药物产品，其中料斗接收具有不规则几何形状和尺寸大于约100μm的颗粒以输送到定量给药机。 将气态流体引导到料斗中以使料斗内的颗粒流化，以便最小化或消除在设置在料斗内的颗粒床内形成空隙。 料斗内的颗粒的流化保持了从料斗到定量器的基本上连续且均匀的颗粒流，这导致形成具有所需重量和粒度分布的包封产品。
-
-
搜索结果
3 条记录 (耗时 0.017 秒)
